 SOLANA BEACH, Calif., April 23, 2021 GLOBE NEWSWIRE -- ClearPoint Neuro, Inc. Nasdaq: CLPT the Company, a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that on September 14, 2020, the Companys Board of Directors approved the grant to Mr. Danilo DAlessandro of i 30,000 shares of restricted common stock and ii a non-qualified stock option awards to purchase 75,000 shares of common stock with an exercise price of 5.80, the closing price on his start date, September 29, 2020. The stock option and restricted share awards will vest in three equal annual installments beginning on September 29, 2021. These awards were granted as an inducement equity award outside of the Companys 2013 Incentive Compensation Plan in accordance with NASDAQ Listing Rule 5635c4, and were made as an inducement material to the acceptance of employment with the Company by Mr. DAlessandro. The options and restricted shares are further subject to the terms and conditions of the award agreements that are exhibits to Mr. DAlessandros employment agreement, which was filed as Exhibit 10.1 to the Companys Current Report on Form 8-K filed with the Securities and Exchange Commission SEC on September 14, 2020, and were previously reflected on Mr. DAlessandros Form 4 filed with the SEC on September 30, 2020. 